| Partruvix (pamiparib) / EMD Serono, BeiGene |
ACTRN12621001183875: Cancer Molecular Screening and Therapeutics (MoST) Program Substudy Addendum 16 substudy 37: Pamiparib |
|
|
| Recruiting | 2 | 16 | | | The University of Sydney, Office for Health and Medical Research, Leukaemia Foundation , Tour de Cure | Cancer | | | | |
NCT04603365: Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer |
|
|
| Withdrawn | 2 | 21 | NA | Pamiparib, BGB-290, PARP Inhibitor BGB-290, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ | Jonsson Comprehensive Cancer Center, BeiGene, Driven To Cure | Clear Cell Papillary Renal Neoplasm, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma, Hereditary Papillary Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Unclassified Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer American Joint Committee on Cancer (AJCC) v8, Stage IV Renal Cell Cancer AJCC v8, Tubulocystic Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma | 05/23 | 05/23 | | |
NCT05489926: A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure |
|
|
| Active, not recruiting | 2 | 15 | RoW | Pamiparib | Zhejiang Cancer Hospital | Epithelial Ovarian Cancer | 06/24 | 12/24 | | |
NCT05376722: A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer |
|
|
| Recruiting | 2 | 30 | RoW | pamiparib, abiraterone, prednisone | Hongqian Guo, First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Soochow University, Nanjing First Hospital, Nanjing Medical University | Neoadjuvant Therapy | 09/23 | 09/24 | | |
ChiCTR2100047016: Pamiparib in combination with bevacizumab in patients with recurrent or metastatic ovarian cancer who had previously received PARPi |
|
|
| Recruiting | 2 | 29 | | pamiparib 60 mg BID plus bevacizumab 7.5 mg/kg Q3W | Hunan Provincial Tumor Hospital; Hunan Provincial Tumor Hospital, self-funded | ovarian cancer | | | | |
| Recruiting | 2 | 40 | RoW | Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel, Pamiparib, Cisplatin, Tislelizumab | The First Affiliated Hospital of Xiamen University | Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer | 04/26 | 04/29 | | |
ChiCTR2200059119: Prospective, single-arm, single-center phase II clinical study of pamiparib combined with TC regimen and bevacizumab in neoadjuvant therapy for untreated advanced ovarian cancer |
|
|
| Not yet recruiting | 2 | 38 | | Pamipalil + paclitaxel + bevacizumab | Fujian Cancer Hospital; Fujian Cancer Hospital, BeiGene (Beijing) Biotechnology Co., Ltd. | ovarian cancer | | | | |
NCT05652283: Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer |
|
|
| Active, not recruiting | 2 | 20 | RoW | Pamiparib, BAIHUIZE, Surufatinib, SULANDA | Bai-Rong Xia | Ovarian Cancer | 05/24 | 05/26 | | |
BRIGHT, NCT05044871: Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 160 | RoW | Pamiparib, Bevacizumab, Tislelizumab, Nab paclitaxel, Bevacizumab + Nab paclitaxel (intense dose-dense) | Tongji Hospital, Qilu Hospital of Shandong University, Hubei Cancer Hospital, Hunan Cancer Hospital, Peking University Cancer Hospital & Institute, Obstetrics and Gynecology Hospital of Zhejiang University, Sun Yat-sen University, Anhui Provincial Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital, Sun Yat-Sen University, Affiliated Hospital of Jiangnan University | Ovarian Cancer | 06/24 | 12/27 | | |
PATAOC, NCT05669768: Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy |
|
|
| Not yet recruiting | 2 | 46 | RoW | Pamiparib/Tamoxifen | Sun Yat-sen University | Ovarian Cancer | 07/24 | 12/24 | | |
NCT05483543: Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy |
|
|
| Recruiting | 2 | 44 | RoW | Pamiparib, BGB-290 | Fudan University | Limited Stage Small Cell Lung Cancer | 12/24 | 12/24 | | |
NCT05327621: Pamiparib in mCRPC With HRD or BRCA1/2 Mutation |
|
|
| Recruiting | 2 | 50 | RoW | Pamiparib, BGB-290 | Sun Yat-sen University | Metastatic Castration-resistant Prostate Cancer | 03/25 | 03/25 | | |
IMPARP-HRD, NCT04985721: A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair Defects |
|
|
| Recruiting | 2 | 60 | RoW | Pamiparib, Tislelizumab | Peter MacCallum Cancer Centre, Australia | Cancer | 08/25 | 08/25 | | |
ChiCTR2300069295: An exploratory clinical study of neoadjuvant therapy with Pamiparib combined with Surufatinib for advanced ovarian cancer |
|
|
| Recruiting | 2 | 20 | | Pamiparib combined with Surufatinib | Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Self-raised | Ovarian Cancer | | | | |
2017-001553-14: A safety and efficacy study of the drug BGB-290 in combination with Temozolomide (TMZ) in patients with ovarian, breast, prostate, lung and stomach cancer. |
|
|
| Not yet recruiting | 1/2 | 250 | Europe | Temozolomide Accord 20 mg hard capsules, Temozolomide Accord 100 mg hard capsules, BGB-290, Capsule, Temozolomide Accord 20 mg hard capsules, Temozolomide Accord 100 mg hard capsules | BeiGene USA, Inc., BeiGene USA, Inc. | Locally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastric cancer), Ovarian, breast, prostate, lung , stomach cancer | | | | |
BGB-290-102, NCT03333915: Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors |
|
|
| Completed | 1/2 | 128 | RoW | Pamiparib, BGB-290 | BeiGene | Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer | 08/20 | 08/21 | | |
|
|
|
NCT03914742: BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations |
|
|
| Completed | 1/2 | 60 | US | PARP Inhibitor BGB-290, BGB-290, PARP, Inhibitor BGB-290, Temozolomide, Temodar, Methazolastone, Therapeutic Conventional Surgery | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), BeiGene | IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma | 10/23 | 10/23 | | |
NCT05494580: Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer |
|
|
| Recruiting | 1/2 | 38 | RoW | Pamiparib, Poly (ADP-ribose) polymerase (PARP) inhibitor, Surufatinib, Tyrosine Kinase Inhibitor | Sun Yat-sen University, Hutchmed | Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Fallopian Tube Carcinosarcoma, Primary Peritoneal Cancer | 08/24 | 08/25 | | |
